Histrelin
Sponsors
Novartis Pharma AG, NRG Oncology, Mayo Clinic
Conditions
Biochemically Recurrent Prostate CarcinomaCastration-resistant Prostate CancerPSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)Prostate AdenocarcinomaRecurrent Castration-Sensitive Prostate CarcinomaRecurrent Prostate CancerStage III Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8
Phase 2
Phase 3
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Active, not recruitingNCT04513717
Start: 2021-01-21End: 2033-12-31Updated: 2026-04-03
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
RecruitingNCT05050084
Start: 2021-12-06End: 2026-11-11Target: 2050Updated: 2026-01-14
PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Active, not recruitingCTIS2023-507970-42-00
Start: 2021-03-31Target: 445Updated: 2026-01-26